<DOC>
	<DOCNO>NCT01668680</DOCNO>
	<brief_summary>Colorectal cancer patient metastasis ( mCRC ) response expensive chemotherapy may toxic +/- exhaust candidate effective convenient maintenance treatment . Objectives : 1 . To define efficacy maintenance chemotherapy low-dose metronomic ( LDM ) regimen , metastatic CRC patient respond FOLFIRI + bevacizumab . 2 . To discover predictive factor response LDM regimen . Hypothesis : 1 . The re-growth residual metastasis slow anti-angiogenic effect LDM chemotherapy . 2 . Serial measurement angiogenic/ inflammatory factor plasma and/or evaluation certain enzyme tumor may discover predictive factor response LDM chemotherapy metastatic CRC patient .</brief_summary>
	<brief_title>Maintenance Metronomic Chemotherapy Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description>At entry research protocol up-till administered treatment Intra Venous FOLFIRI+BEVACIZUMAB stopped.Instead , research oral treatment initiate take daily ambulatory basis monthly re-evaluation . If disease progress original FOLFIRI+BEVACIZUMAB treatment consider re-institution .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>1 . Histologic ( cytologic ) proof colorectal carcinoma ( CRC ) . 2 . Age : 18 80 . 3 . Sex : sex . 4 . Previous treatment metastatic disease limit FOLFIRI+ bevacizumab . 5 . Prior adjuvant chemotherapy , fluoropyrimidine and/or Oxaliplatin , allow . 6 . Prior radiotherapy , either adjuvant treatment palliation metastatic site allow , provide nonirradiated foci disease evaluation . 7 . Persistent remission , either complete , partial minimal response ( CR , PR MR ) stable disease ( SD ) , one year+/one month initiation first line treatment mCRC . 8 . Asymptomatic patient break chemotherapy . 9 . Intact organ function , include complete blood count ( CBC ) show normal value toxicity limit grade 1 blood chemistry ( SMA ) show liver renal function &lt; 1.5 upper normal limit ( UNL ) . 10 . Capability understand sign inform consent . 1 . Concurrent cancer ( except BCC squamous cell carcinoma skin ) . 2 . Inability adhere monthly visit oncology unit evaluation . 3 . Presence brain metastasis . 4 . Any current recent ( within last month ) continuous treatment steroid NSAIDs , therapeutic dos anticoagulant reason . 5 . Previous radiotherapy site measurable disease . 6 . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac include arrhythmia , hepatic renal disease ) , and/or existence active peptic ulcer ( clinically and/or gastroscopy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Metronomic Chemotherapy</keyword>
	<keyword>Anti-Angiogenic</keyword>
	<keyword>Maintenance Treatment</keyword>
	<keyword>Colorectal Cancer Metastatic</keyword>
</DOC>